JP Morgan Chase
BCRX icon

JP Morgan Chase’s BioCryst Pharmaceuticals BCRX Stock Holding History

JP Morgan Chase’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$1.15M – 6690
2022
Q4 		$1.15M Buy
+100,000
New +$1.25M ﹤0.01% 3945
2019
Q1 		– Sell
-90,000
Closed -$726K – 5758
2018
Q4 		$726K Sell
90,000
-3,500
-4% -$27.2K ﹤0.01% 3932
2018
Q3 		$713K Buy
+93,500
New +$628K ﹤0.01% 4105

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

JP Morgan Chase's BCRX Position: Q1 2026 in Review

JP Morgan Chase increased its BioCryst Pharmaceuticals (BCRX) stake by 83% in Q1 2026, buying an estimated $5.43M and bringing the position to 1,541,978 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

JP Morgan Chase first reported a position in BCRX in Q2 2013 and has held it in 43 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • JP Morgan Chase held 1,541,978 shares of BioCryst Pharmaceuticals worth $14.6M as of Q1 2026.
  • JP Morgan Chase bought 698,608 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $5.43M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2353 holding.
  • JP Morgan Chase first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.